{"id":765785,"date":"2023-06-23T16:33:13","date_gmt":"2023-06-23T20:33:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/"},"modified":"2023-06-23T16:33:13","modified_gmt":"2023-06-23T20:33:13","slug":"mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/","title":{"rendered":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"start\">NEW YORK, June  23, 2023  (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (NASDAQ: MRSN) securities. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rbnuKaVsShHAAStQjpMA1ENCl33sFtw-SDcIIAWKnmMeH3pvQVe4uf_Sl8NZo2if9a7K-Rp8jnV2FTzVdNA7fBITKo7i_PpbJUqIqprfPfrQlapADeTghTgYioKkhq3Nf8VGHJn0yl8KQkO3b_PjmQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Click Here To Join Investigation.<\/u><\/a><\/p>\n<p align=\"start\">\n        <strong>If you purchased Mersana securities and would like to discuss our investigation, please <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9ugBT3TX2tcRN-8oVAqmLFxhk8niZLtbZfc55_nMqEKQJIkCP5wokI_ZI0N1H2SkDJisoiixuVLixVMBBenaCvzehh5Hxv_J8eczvT1rcJgfkYJmcr-9xsSaonamj-bU\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>click here<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong>, or contact us by emailing <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IPYhwWuiO-FezsMTdgsow58YkfkyWaZi-icy55D3--Q-aLF9Flh76UesNDMn0v30XW6CW-npMjnqAdv7amOKSZEhQwkwj_yQ11xxtL4tY6c=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>jcampisi@kaplanfox.com<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong> or calling (212) 329-8571. <\/strong>\n      <\/p>\n<p align=\"start\">On June 15, 2023, Mersana, a clinical-stage biopharmaceutical company, announced that \u201cthe U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company\u2019s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer. UPLIFT, Mersana\u2019s ongoing clinical trial of UpRi in platinum-resistant ovarian cancer, completed enrollment in October 2022.\u201d The June 15 press release issued by the company states that \u201c[t]he partial clinical hold follows a submission by Mersana of a recent aggregate safety report of all patients dosed with UpRi (approximately 560 patients) evaluating bleeding events.\u201d As stated in the release, \u201cMersana\u2019s recent assessment determined that serious bleeding events appear to occur at a higher rate than background. While most bleeding cases in this aggregate safety analysis were low-grade, five (&lt;1%) Grade 5 (fatal) bleeding events were observed among the approximately 560 patients dosed to date. The causes of bleeding events remain under investigation.\u201d<\/p>\n<p align=\"start\">Mersana\u2019s stock price fell $5.66 per share, or 59.27%, to close at $3.89 per share on June 15, 2023 in response to the news issued in the press release.<\/p>\n<p align=\"start\">\n        <strong>WHY CONTACT KAPLAN FOX<\/strong> &#8211; Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox &amp; Kilsheimer LLP, you may visit our website at www.kaplanfox.com.<\/p>\n<p align=\"start\">If you have any questions about this investigation, please contact:<\/p>\n<p align=\"start\">Jeffrey P. Campisi <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 800 Third Avenue, 38th Floor <br \/> New York, New York 10022 <br \/> (212) 329-8571 <br \/> E-mail: jcampisi@kaplanfox.com<\/p>\n<p align=\"start\">Laurence D. King <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 1999 Harrison Street, Suite 1560 <br \/> Oakland, California 94612 <br \/> (415) 772-4704 <br \/> Fax: (415) 772-4707 <br \/> E-mail: lking@kaplanfox.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/YmJmNGQ5YTktMTNkZC00NThmLTgwNWItODUxMWQ0YjJlZjJkLTEwMzE5OTk=\/tiny\/Kaplan-Fox-Kilsheimer-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (NASDAQ: MRSN) securities. Click Here To Join Investigation. If you purchased Mersana securities and would like to discuss our investigation, please click here , or contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571. On June 15, 2023, Mersana, a clinical-stage biopharmaceutical company, announced that \u201cthe U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company\u2019s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer. UPLIFT, Mersana\u2019s ongoing clinical trial of UpRi in platinum-resistant ovarian cancer, completed enrollment in October 2022.\u201d &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765785","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (NASDAQ: MRSN) securities. Click Here To Join Investigation. If you purchased Mersana securities and would like to discuss our investigation, please click here , or contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571. On June 15, 2023, Mersana, a clinical-stage biopharmaceutical company, announced that \u201cthe U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company\u2019s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer. UPLIFT, Mersana\u2019s ongoing clinical trial of UpRi in platinum-resistant ovarian cancer, completed enrollment in October 2022.\u201d &hellip; Continue reading &quot;Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-23T20:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations\",\"datePublished\":\"2023-06-23T20:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/\"},\"wordCount\":399,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/\",\"name\":\"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\",\"datePublished\":\"2023-06-23T20:33:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/","og_locale":"en_US","og_type":"article","og_title":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk","og_description":"NEW YORK, June 23, 2023 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating potential claims on behalf of investors who purchased Mersana Therapeutics, Inc. (NASDAQ: MRSN) securities. Click Here To Join Investigation. If you purchased Mersana securities and would like to discuss our investigation, please click here , or contact us by emailing jcampisi@kaplanfox.com or calling (212) 329-8571. On June 15, 2023, Mersana, a clinical-stage biopharmaceutical company, announced that \u201cthe U.S. Food and Drug Administration (FDA) has issued a partial clinical hold pausing new patient enrollment in UP-NEXT and UPGRADE-A, the company\u2019s ongoing clinical trials of UpRi in platinum-sensitive ovarian cancer. UPLIFT, Mersana\u2019s ongoing clinical trial of UpRi in platinum-resistant ovarian cancer, completed enrollment in October 2022.\u201d &hellip; Continue reading \"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-23T20:33:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations","datePublished":"2023-06-23T20:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/"},"wordCount":399,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/","name":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=","datePublished":"2023-06-23T20:33:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MzYwOSM1NjYyMjY3IzIwMjA4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mersana-therapeutics-shareholder-alert-kaplan-fox-launches-investigation-into-mersana-therapeutics-inc-for-potential-securities-violations\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mersana Therapeutics Shareholder Alert: Kaplan Fox Launches Investigation into Mersana Therapeutics, Inc. for Potential Securities Violations"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765785"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765785\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}